Heritage Investors Management Corp Grows Stake in Eli Lilly and Company $LLY

Key Points

• Heritage Investors Management Corp increased its Eli Lilly stake by 12.9% in the second quarter, bringing its holdings to 11,056 shares valued at approximately $13.3 million. Institutional investors collectively own 82.53% of LLY.
• Eli Lilly reported strong quarterly results, with revenue rising 47.7% year over year to $22.97 billion and EPS of $8.38, well above consensus estimates. The company issued fiscal 2026 EPS guidance of $35.50–$36.50, supported by growth in Mounjaro, Zepbound and other medicines.
• Analysts maintain a broadly positive view, with 25 of 30 covering analysts rating the stock Buy or Strong Buy and an average price target of $1,292.18. However, LLY trades at a high valuation of about 39.7 times earnings, while recent insider sales could add near-term pressure.

Heritage Investors Management Corp grew its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 12.9% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 11,056 shares of the company's stock after purchasing an additional 1,261 shares during the quarter. Heritage Investors Management Corp's holdings in Eli Lilly and Company were worth $13,261,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of LLY. Vanguard Group Inc. grew its position in Eli Lilly and Company by 1.2% in the fourth quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company's stock valued at $88,087,193,000 after acquiring an additional 1,006,885 shares in the last quarter. State Street Corp raised its stake in shares of Eli Lilly and Company by 1.8% during the fourth quarter. State Street Corp now owns 35,361,916 shares of the company's stock valued at $38,002,744,000 after purchasing an additional 635,358 shares during the period. Morgan Stanley lifted its position in shares of Eli Lilly and Company by 2.7% during the fourth quarter. Morgan Stanley now owns 15,593,019 shares of the company's stock worth $16,757,510,000 after purchasing an additional 407,166 shares in the last quarter. Capital World Investors lifted its position in shares of Eli Lilly and Company by 0.4% during the fourth quarter. Capital World Investors now owns 15,031,750 shares of the company's stock worth $16,154,619,000 after purchasing an additional 61,851 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its stake in shares of Eli Lilly and Company by 10.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 14,910,505 shares of the company's stock valued at $16,024,022,000 after purchasing an additional 1,432,069 shares during the period. Hedge funds and other institutional investors own 82.53% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on LLY. Cantor Fitzgerald raised their price target on shares of Eli Lilly and Company from $1,350.00 to $1,410.00 and gave the company an "overweight" rating in a report on Thursday, August 6th. Berenberg Bank boosted their price objective on shares of Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the stock a "hold" rating in a report on Monday, June 22nd. BMO Capital Markets reissued an "outperform" rating and issued a $1,400.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, August 6th. UBS Group set a $1,376.00 target price on Eli Lilly and Company in a research note on Friday, August 7th. Finally, Bank of America lifted their target price on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a "buy" rating in a research report on Friday, July 10th. One analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $1,292.18.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The U.K. regulator approved Lilly’s once-daily oral weight-loss pill, Foundayo (orforglipron), giving the company a potentially important first-mover advantage for an obesity pill in Europe. The approval expands Lilly’s addressable market beyond injectable treatments such as Mounjaro and Zepbound. Eli Lilly Just Scored Europe's First Weight Loss Pill Approval
• Positive Sentiment: Lilly is expanding its obesity pipeline with a new Phase 1 macupatide study in Japan. Although early-stage, the trial reinforces the company’s efforts to develop additional weight-management therapies and support long-term growth. Lilly Expands Obesity Pipeline With Fresh Macupatide Trial in Japan
• Positive Sentiment: Recent earnings showed continued operating momentum: quarterly revenue rose about 48% year over year to roughly $23 billion, while adjusted EPS beat expectations. Growth was led by Mounjaro, Zepbound and other key medicines, and management raised full-year 2026 guidance. Foundayo also generated an initial $98 million in quarterly sales. 5 Revealing Analyst Questions From Eli Lilly’s Q2 Earnings Call
• Neutral Sentiment: Analysts continue to view LLY as a fundamental leader, with reported price targets generally above the current trading level. However, the stock is approaching a technical buy point after a large earnings-driven advance, making valuation and chart resistance important near-term considerations. Eli Lilly Stock Nears Buy Point After Earnings-Fueled Gains
• Negative Sentiment: Insider-selling headlines may be adding pressure: executives have sold shares in recent months, including a reported 2,000-share sale by CFO and Chief Accounting Officer Donald Zakrowski. Lilly also trades at a demanding earnings multiple, leaving the stock sensitive to profit-taking or any signs of slower obesity-drug growth. Donald Zakrowski Sells 2,000 Shares of Eli Lilly Stock

Eli Lilly and Company Stock Up 0.2%

LLY stock opened at $1,182.24 on Monday. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41. The firm has a 50 day simple moving average of $1,170.82 and a 200-day simple moving average of $1,052.69. The company has a market capitalization of $1.11 trillion, a P/E ratio of 39.67, a PEG ratio of 1.39 and a beta of 0.51. Eli Lilly and Company has a twelve month low of $685.15 and a twelve month high of $1,249.45.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The firm had revenue of $22.97 billion for the quarter, compared to analysts' expectations of $20.82 billion. During the same period in the prior year, the company posted $6.31 earnings per share. The firm's quarterly revenue was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, equities research analysts predict that Eli Lilly and Company will post 36.35 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be given a $1.73 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company's payout ratio is presently 23.22%.

Insider Transactions at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 2,000 shares of Eli Lilly and Company stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the transaction, the chief accounting officer directly owned 1,526 shares in the company, valued at approximately $1,808,325.26. This trade represents a 56.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the business's stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the completion of the sale, the executive vice president directly owned 11,875 shares of the company's stock, valued at approximately $14,131,250. This represents a 29.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.14% of the company's stock.

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source